G. Chan

发表

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis

J. Silverberg, J. Thyssen, M. Gooderham, 2020, JAMA dermatology.

Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials

J. Isaacs, G. Chan, R. Panaccione, 2020, Digestive Diseases and Sciences.

Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis

C. Flohr, Hidetoshi Takahashi, G. Chan, 2021, JAMA dermatology.

Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis.

B. Sands, G. Chan, C. Nduaka, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials.

B. Sands, G. D'Haens, G. Chan, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

The Jak Inhibitor CP‐690,550 Preserves the Function of CD4+CD25brightFoxP3+ Regulatory T Cells and Inhibits Effector T Cells

W. Weimar, G. Chan, L. J. van der Laan, 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme

A. Thorpe, G. Chan, C. Nduaka, 2020, Journal of Crohn's & colitis.

Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program

G. Rogler, A. Thorpe, G. Chan, 2020, Inflammatory bowel diseases.

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials

S. Vermeire, P. Higgins, B. Sands, 2017, Gut.

Population Pharmacokinetic Analysis of Mycophenolic Acid Coadministered With Either Tasocitinib (CP-690,550) or Tacrolimus in Adult Renal Allograft Recipients

M. Melcher, S. Busque, G. Chan, 2010, Therapeutic drug monitoring.

Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis.

G. Chan, J. Krueger, P. Changelian, 2009, The Journal of investigative dermatology.

Effect of CP‐690,550, an Orally Active Janus Kinase Inhibitor, on Renal Function in Healthy Adult Volunteers

S. Swan, G. Chan, N. Lawendy, 2009, Journal of clinical pharmacology.

The Effect of the JAK Inhibitor CP-690,550 on Peripheral Immune Parameters in Stable Kidney Allograft Patients

W. Weimar, G. Chan, C. Baan, 2009, Transplantation.

Phase 1 Dose‐Escalation Study of CP‐690 550 in Stable Renal Allograft Recipients: Preliminary Findings of Safety, Tolerability, Effects on Lymphocyte Subsets and Pharmacokinetics

W. Weimar, M. Pescovitz, D. Brennan, 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Evaluation of the effect of fluconazole and ketoconazole on the pharmacokinetics of tofacitinib in healthy adult subjects

G. Chan, R. Labadie, G. Ni, 2014, Clinical pharmacology in drug development.

Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib

S. Vermeire, A. Thorpe, G. Chan, 2018, Inflammatory bowel diseases.

Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open

B. Sands, J. Lindsay, G. Chan, 2019, Alimentary pharmacology & therapeutics.

704 Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: An Interim Analysis of an Open-Label, Long-Term Extension Study With up to 5.5 Years of Treatment

A. Thorpe, S. Bloom, G. Chan, 2019, American Journal of Gastroenterology.

Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: An Interim Analysis of an Open-Label, Long-Term Extension Study With up to 4.9 Years of Treatment

A. Thorpe, S. Bloom, G. Chan, 2018, American Journal of Gastroenterology.

The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Tofacitinib, a Janus Kinase Inhibitor, in Humans

G. S. Walker, C. Prakash, G. Chan, 2014, Drug Metabolism and Disposition.

DMD054940 759..773

G. S. Walker, C. Prakash, G. Chan, 2014 .

DOP61 Tofacitinib, an oral, small-molecule Janus kinase inhibitor, in the treatment of ulcerative colitis: Analysis of an open-label, long-term extension study with up to 5.9 years of treatment

A. Thorpe, S. Bloom, G. Chan, 2020 .

Inhibitors Targeting JAK3

G. Chan, P. Changelian, 2012 .

Therapeutic targeting of Janus kinases

J. O’Shea, A. Laurence, M. Pesu, 2008, Immunological reviews.

Monitoring of the Immunomodulatory Effect of CP-690,550 by Analysis of the JAK/STAT Pathway in Kidney Transplant Patients

W. Weimar, G. Chan, C. Baan, 2009, Transplantation.

A Supratherapeutic Dose of the Janus Kinase Inhibitor Tasocitinib (CP‐690,550) Does Not Prolong QTc Interval in Healthy Participants

G. Chan, S. Krishnaswami, E. Kudlacz, 2011, Journal of clinical pharmacology.

Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis

G. Chan, L. Peyrin-Biroulet, G. Lichtenstein, 2023, Digestive Diseases and Sciences.

Randomized Phase 2b Trial of Tofacitinib (CP‐690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year

J. Friedewald, Y. S. Kim, W. Weimar, 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

DOP026 Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open

B. Sands, J. Lindsay, G. Chan, 2018 .

DOP43 Long-term efficacy of tofacitinib in patients who received extended induction therapy: results of the OCTAVE open study for tofacitinib delayed responders

M. Dubinsky, D. Rubin, G. Chan, 2019, Journal of Crohn's and Colitis.

706 Impact of Baseline Corticosteroid Therapy on Tofacitinib Induction Efficacy and Infection Risk in Patients With Ulcerative Colitis: Data From Global Clinical Trials

G. Chan, L. Peyrin-Biroulet, G. Lichtenstein, 2019, American Journal of Gastroenterology.

Phase 3 Efficacy and Safety of Abrocitinib in Adults with Moderate-to-Severe Atopic Dermatitis After Switching from Dupilumab (JADE EXTEND).

S. Shumack, G. Chan, H. Valdez, 2022, Journal of the American Academy of Dermatology.

Long‐term safety and tolerability of oral tofacitinib in patients with Crohn’s disease: results from a phase 2, open‐label, 48‐week extension study

P. Higgins, G. D'Haens, G. Chan, 2017, Alimentary pharmacology & therapeutics.

Long‐term safety and tolerability of oral tofacitinib in patients with Crohn’s disease: results from a phase 2, open‐label, 48‐week extension study

P. Higgins, G. D'Haens, G. Chan, 2017, Alimentary Pharmacology and Therapeutics.

Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program

B. Sands, G. Chan, C. Nduaka, 2021, Inflammatory bowel diseases.

726 Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates in the Tofacitinib Ulcerative Colitis Clinical Program

A. Thorpe, G. Chan, W. Reinisch, 2019, American Journal of Gastroenterology.

705 Tofacitinib for the Treatment of Ulcerative Colitis: An Update on the Analysis of Malignancy Rates From the UC Clinical Program

G. Rogler, A. Thorpe, G. Chan, 2019, American Journal of Gastroenterology.

671 An Update on the Analysis of Non-Melanoma Skin Cancer in the Tofacitinib Ulcerative Colitis Program

B. Sands, L. Baidoo, G. Chan, 2019, American Journal of Gastroenterology.

Evaluation of the Effect of Tofacitinib Exposure on Outcomes in Kidney Transplant Patients

G. Russ, S. Busque, K. Budde, 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers

G. Chan, S. Krishnaswami, V. Chow, 2015, Clinical pharmacology in drug development.

Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end‐stage renal disease

G. Chan, Cunshan Wang, S. Krishnaswami, 2014, Journal of clinical pharmacology.

Efficacy and Safety of a Tofacitinib-based Immunosuppressive Regimen After Kidney Transplantation: Results From a Long-term Extension Trial

J. Friedewald, S. Busque, K. Budde, 2018, Transplantation direct.

P684 The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: updated results from the tofacitinib ulcerative colitis clinical programme

B. Sands, G. Chan, C. Nduaka, 2018, Journal of Crohn's and Colitis.

P512 Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib

S. Vermeire, A. Thorpe, G. Chan, 2018 .

Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib: 604

S. Vermeire, A. Thorpe, G. Chan, 2017 .